vocimagene amiretrorepvecflucytosine experimental combination drug involving gene therapy agent prodrug candidate drug treat brain cancers vocimagene amiretrorepvec also known toca gene therapy agent wherein payload gene encoding cytosine deaminase cd replicating nonlytic retroviral flucytosine also known toca fc antifungal drug used extendedrelease formulation flucytosine prodrug cancer drug cross barrier well flucytosine combination drug designed used brain tumor removed surgically vocimagene amiretrorepvec intended injected tissues lining hole tumor region called margin virus replicates cells dividing words cancer cells left margin immune cells present flucytosine administered person converted cells cd expressed cells infected gene therapy july ema granted combination priority review status fda granted breakthrough therapy designation fda fast track designation recurrent hgg orphan designation treatment combination development tocagen july phase trials underway recurrent astrocytoma recurrent high grade httpsenwikipediaorgwikivocimageneamiretrorepvecflucytosine